Find clinical trials

In patients with previously untreated chronic lymphocytic leukemia (CLL). The duration of each cycle is 28 days. Arm A: sonrotoclax + zanubrutinib up to 15 cycles. Arm B: venetoclax plus acalabrutinib up to 14 cycles.

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).

The aim of this study is to evaluate the efficacy, safety and tolerability of BMB-101 in adults with either classic Absence Epilepsy (with or without Eyelid Myoclonia (EEM; Jeavons Syndrome)) or Developmental Epileptic Encephalopathy (DEE). A maximum of 20 participants will participate. Male or females, aged 18-65 yrs. Study duration is 4-5 months. For participants with classic absence epilepsy, there will be a 1-month screening period, then 8 weeks on BMB-101, and then a 1-month follow-up period. There will be 5 clinic visits and at least 4 phone calls. For participants with DEE, there will be a 1-month screening period, then 12 weeks on BMB-101, and then a 1-month follow-up period. There will be 6 clinic visits and at least 3 phone calls. The goal of the study is to assess the effects of BMB-101 in reducing the number of seizures. This will be done by comparing the frequency of seizures on EEGs and participant diaries.

The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with BNT327 as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.

This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.